Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?

Leukemia & Lymphoma
C DazziM Marangolo

Abstract

We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 microg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of CD34+ cells considered as the target for each high-dose chemotherapy was > or = 2 x 10(6) /Kg/bw. Fifteen leukaphereses procedures were necessary in group A, while 16 procedures were performed in group B. We did not observe any difference between the two groups in terms of CD34+ cells/microl in the peripheral blood (117 vs 78; p = NS), whereas in the aphereses product we found a significant difference between the two groups of patients in terms of CD34+ cells (6.41 vs 2.89 x 10(6) /Kg/bw; p = .009), CFU-GM (82.5 vs 52.3 x 10(4) /Kg/bw; p = .04). Interestingly, we noted a different distribution of CD34+/33- cells between the 2 groups (mean value 39% vs 65%; p < .05), whereas we did not find any differences regarding CD34+/38-, CD34+/Thy1+, CD34+/HLADR-. The higher number of CFU-GM/Kg/bw collected in the former group did not translate into a superior plating efficiency (27.75 vs 30.29). Furthermore, we observed a stro...Continue Reading

References

Aug 16, 1986·Lancet·L B ToC A Juttner
Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BeyerW Stieger
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W BensingerC Weaver
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A L PecoraJ A Brochstein

❮ Previous
Next ❯

Citations

Dec 18, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sibel HacıoğluAli Keskin
Mar 13, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sinem Civriz BozdağFevzi Altuntaş
Jan 27, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Mehmet Hilmi DoguFevzi Altuntaş
Sep 6, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sinem Civriz Bozdag, Osman Ilhan
Jun 24, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hakan GokerYahya Buyukasik
Aug 13, 2011·Blood·L Bik ToKirsten E Herbert
Mar 31, 2010·Clinical Journal of Oncology Nursing·Hollie DevineKathleen McDermott
Jan 14, 2009·Bone Marrow Transplantation·W BensingerJ M McCarty
Dec 10, 2009·The Annals of Pharmacotherapy·Lindsay L RosenbeckPatrick J Kiel
Oct 13, 2016·Transfusion·Shan Yuan, Shirong Wang
Oct 28, 2017·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Rajiv KumarVelu Nair
Aug 23, 2021·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Ahmet SariciMustafa Ozgul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.